Safi Biotherapeutics specializes in the scalable ex vivo manufacturing of tailored red blood cells for acute and chronic transfusions, addressing critical shortages in blood supply. Their technology enables on-demand production of blood products, ensuring high consistency and economic viability for specific medical needs, such as trauma care and sickle cell disease transfusions.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods of obtaining red blood cells rely heavily on donor blood, which faces challenges such as supply shortages, logistical complexities, and the risk of incompatibility for patients with specific medical needs. Traditional blood banking systems struggle to provide tailored blood products on demand, particularly in emergency situations or for individuals with rare blood types.
Solution
Safi Biotherapeutics is developing a scalable ex vivo manufacturing platform for producing tailored red blood cells, aiming to overcome the limitations of donor-dependent blood supplies. Their technology focuses on generating consistent and economically viable blood products on demand, addressing critical needs in trauma care, sickle cell disease transfusions, and other specialized medical applications. By optimizing blood stem cell expansion, bioprocessing, and cryostorage, Safi Biotherapeutics seeks to provide allogeneic blood products tailored to specific patient requirements. The company is integrating expertise in cell therapy manufacturing to achieve appropriate scale and high product consistency.
Target Audience
The primary target audience includes hospitals, trauma centers, blood banks, and medical facilities requiring consistent and readily available supplies of red blood cells, particularly for patients with unique transfusion needs or those facing blood shortages.
Features
- Scalable ex vivo red blood cell manufacturing platform
- On-demand production of allogeneic blood products
- Tailored red blood cells for specific transfusion needs (e.g., sickle cell disease)
- Bioprocessing optimization for high consistency and yield
- Integration of blood stem cell expansion and differentiation technologies
- Cryostorage solutions for long-term preservation of manufactured blood cells